Research effects
TB500 is a synthetic peptide corresponding to the active region of Thymosin Beta-4 (sequence LKKTETQ). It modulates cytoskeletal dynamics via actin binding, promotes endothelial and keratinocyte migration, downregulates inflammatory chemokines, and stimulates angiogenesis, thereby accelerating tissue repair in skin and corneal wound models. In myocardial infarction models, it inhibits cardiac fibrosis through the miR139-5p/ROCK1 pathway. Importantly, TB500 is not FDA-approved for any clinical indication and is available solely as a research product; human safety and efficacy data remain insufficient, warranting cautious use.
